IPOs and the New FDA
This article was originally published in RPM Report
Ironwood Pharmaceuticals and Anthera Pharmaceuticals tested the public offering market in early 2010. The two companies share a positive reading on a thaw in the freeze on public financings, but they show different attitudes on the nature of the regulatory climate. To Ironwood, past regualtory difficulties for other companies are an opportunity. Ironwood does not see much of a threat from new FDA safety tools. Anthera sees the threat but says it has a plan to navigate the new authorities.
You may also be interested in...
Entereg is the most important new drug approved by FDA so far in 2008. Not because of its commercial prospects, which are far more limited than development partners GSK and Adolor once hoped for, but because it is a precedent-setting use of the agency's new drug safety authorities-and a case study in how those new tools can save a drug that might otherwise never have been marketed at all.
Some Democratic senators are not fans of FDA’s approval of Biogen/Eisai’s Aduhelm, and are even more critical of the price of the Alzheimer’s therapy. That is providing a new hook to urge action on creating a federal price ‘negotiation’ program – but not any more clarity on a viable path to enacting one.
Patrizia Cavazzoni, FDA Center for Drug Evaluation and Research director, knows she has ‘huge shoes’ to fill. Convincing the CDER staff that she is capable of doing so is job one.